Stockscreener 앱 받기
0.59
0.09%
0.0375
전일 마감가:
$0.5525
열려 있는:
$0.553
하루 거래량:
2,953
Relative Volume:
0.07
시가총액:
$18.06M
수익:
-
순이익/손실:
$-563.30K
주가수익비율:
-2.9559
EPS:
-0.1996
순현금흐름:
$-22.23M
1주 성능:
-9.92%
1개월 성능:
-28.18%
6개월 성능:
-45.78%
1년 성능:
-76.47%
1일 변동 폭
$0.553
$0.59
1주일 범위
$0.5118
$0.6804
52주 변동 폭
$0.5118
$2.4499
Promis Neurosciences Inc Stock (PMN) Company Profile
명칭
Promis Neurosciences Inc
전화
416-847-6898
주소
SUITE 200, 1920 YONGE STREET, TORONTO
PMN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
0.59 | 18.06M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
478.44 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.00 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
578.62 | 33.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
228.36 | 29.29B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
232.77 | 22.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Promis Neurosciences Inc 주식(PMN)의 최신 뉴스
ProMIS Neurosciences stock hits 52-week low at $0.62 By Investing.com - Investing.com South Africa
ProMIS Neurosciences stock hits 52-week low at $0.62 - Investing.com India
Promis Neurosciences chief scientific officer buys $14,595 in shares - MSN
ProMIS Neurosciences’ (PMN) Buy Rating Reaffirmed at Guggenheim - Defense World
ProMIS Neurosciences Reports 2024 Financial Turnaround - TipRanks
ProMIS Neurosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PROMIS NEUROSCIENCES Earnings Results: $PMN Reports Quarterly Earnings - Nasdaq
ProMIS Neurosciences Inc. (PMN) reports earnings - Quartz
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights - The Manila Times
Form 424B5 ProMIS Neurosciences - StreetInsider
ProMIS Neurosciences Inc. SEC 10-K Report - TradingView
ProMIS Neurosciences Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
ProMIS to present neurodegenerative disease research By Investing.com - Investing.com Australia
New Diagnostics And Treatments Transform Neurodegenerative Disease Care - Evrim Ağacı
ProMIS to present neurodegenerative disease research - Investing.com India
ProMIS Neurosciences Showcases Preclinical Data on - GlobeNewswire
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference - Yahoo Finance
ProMIS Neurosciences (PMN) Expected to Announce Quarterly Earnings on Monday - Defense World
Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Ionis Pharma - Barchart
Multiple System Atrophy Market to Reach New Heights in Growth - openPR
ProMIS to present vaccine data at neurology meeting By Investing.com - Investing.com Australia
ProMIS to present vaccine data at neurology meeting - Investing.com India
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting - The Manila Times
ProMIS Neurosciences to Present Preclinical Data on Computational Vaccine Development for Neurodegenerative Diseases at AAN Annual Meeting - Nasdaq
ProMIS Neurosciences Showcases Preclinical Data on Platform - GlobeNewswire
PROMIS NEUROSCIENCES Earnings Preview: Recent $PMN Insider Trading, Hedge Fund Activity, and More - Nasdaq
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference - GlobeNewswire
ProMIS Neurosciences’ (PMN) “Buy” Rating Reiterated at Guggenheim - Defense World
ProMIS Neurosciences begins Alzheimer’s trial dosing - Investing.com India
ProMIS Neurosciences Advances Phase 1b Alzheimer’s Trial - TipRanks
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement - The Manila Times
ProMIS Neurosciences begins Alzheimer’s trial dosing By Investing.com - Investing.com South Africa
ProMIS Neurosciences begins Alzheimer's trial dosing - Investing.com
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease - GlobeNewswire
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for ... - The Bakersfield Californian
Multiple System Atrophy Clinical Trials and Pipeline 2025: EMA, - openPR
ProMIS Neurosciences Announces COO Position Termination - TipRanks
ProMIS Neurosciences stock hits 52-week low at $0.85 By Investing.com - Investing.com Nigeria
ProMIS Neurosciences dismisses COO position - MSN
ProMIS Neurosciences announces COO departure - Investing.com
ProMIS Neurosciences stock hits 52-week low at $0.85 - Investing.com
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight - GlobeNewswire Inc.
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel - GlobeNewswire
Promis Neurosciences Inc (PMN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Promis Neurosciences Inc 주식 (PMN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Shafmaster Madge K. | Director |
Sep 24 '24 |
Buy |
1.30 |
70,000 |
91,028 |
208,333 |
| Shafmaster Madge K. | Director |
Sep 23 '24 |
Buy |
1.28 |
70,000 |
89,656 |
138,333 |
| Shafmaster Madge K. | Director |
Sep 20 '24 |
Buy |
1.25 |
60,000 |
75,066 |
68,333 |
| GORDON MICHAEL S | 10% Owner |
Sep 16 '24 |
Buy |
1.22 |
76,931 |
94,071 |
76,931 |
| GORDON MICHAEL S | 10% Owner |
Sep 17 '24 |
Buy |
1.40 |
16,292 |
22,809 |
93,223 |
| Kirwin Patrick D. | Director |
Aug 14 '24 |
Buy |
1.25 |
10,000 |
12,492 |
62,983 |
3.44%
0.27%
자본화:
|
볼륨(24시간):